Adaptive Biotechnologies CORP Form 4 insider transactions

Director Peter M Neupert reports acquisition of Adaptive Biotechnologies stock and options in a Form 4 filing.

Robert Hershberg, a director at Adaptive Biotechnologies, acquired shares and stock options on March 4, 2025, according to a Form 4 filing.

Director Michelle Griffin reports acquisition and disposal of Adaptive Biotechnologies stock and stock options under a pre-arranged trading plan.

Adaptive Biotechnologies CEO Chad Robins exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Chad Robins, CEO and Chairman of Adaptive Biotechnologies, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies' Chief Financial Officer, Kyle Piskel, sold 248 shares of common stock to cover tax obligations related to the vesting of Restricted Stock Units (RSUs).

Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies, exercised stock options to acquire 5,000 shares of common stock at $1.98 per share.

Stacy L. Taylor, SVP and General Counsel of Adaptive Biotechnologies, sold 26,922 shares of common stock at a weighted-average price of $4.4974 on August 22, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Financial Officer of Adaptive Biotechnologies, Kyle Piskel, reports acquisition and disposal of common stock.

Director Peter M Neupert exercised stock options to acquire 15,000 shares of Adaptive Biotechnologies Corp at $0.84 per share on March 12, 2024.

Michael J Pellini, a director of Adaptive Biotechnologies, acquired shares and stock options on March 4, 2024.

Director Katey Einterz Owen of Adaptive Biotechnologies Corp reports acquisition of common stock and stock options.

Director Peter Neupert acquired shares and options in Adaptive Biotechnologies on March 4, 2024.

Robert Hershberg, a director at Adaptive Biotechnologies, acquired shares and stock options on March 4, 2024, according to a recent SEC filing.

Director Michelle Griffin of Adaptive Biotechnologies Corp. reports the acquisition of stock options and common stock, along with the disposal of common stock, in a recent SEC filing.

Kyle Piskel, Principal Accounting Officer of Adaptive Biotechnologies, sold shares to cover tax withholding obligations related to vesting RSUs.

Stacy L Taylor, SVP and General Counsel of Adaptive Biotechnologies, reports acquisition and disposal of company stock and stock options to cover tax obligations.

Francis Lo, Chief People Officer of Adaptive Biotechnologies, reports the acquisition and disposal of company stock and stock options related to vesting RSUs and tax obligations.

Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies, sold shares to cover tax withholding obligations related to RSU vesting.

President Julie Rubinstein of Adaptive Biotechnologies Corp reports acquisition and disposition of common stock to cover tax obligations related to vesting RSUs.

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, reports changes in beneficial ownership of common stock on March 4, 2024.

Adaptive Biotechnologies' CFO, Tycho Peterson, reports the acquisition and disposition of company stock to cover tax obligations related to RSU vesting.

Chad Robins, CEO and Chairman of Adaptive Biotechnologies, reports the acquisition and disposal of company stock to cover tax obligations related to RSU vesting.

Susan Bobulsky, Chief Commercial Officer, MRD at Adaptive Biotechnologies, sold shares to cover tax obligations related to the vesting of Restricted Stock Units (RSUs) and acquired stock options.